Cancer Supportive Care Drugs Market Size, Share, Trends, Demand & Growth 2026 | by Johnson & Johnson, Novartis AG, F.Hoffmann La-Roche Ltd., Amgen, Inc., Baxter International, etc
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Cancer supportive care refers to care given to the patients suffering from different types of cancer. The supportive care is intended to provide relief to suffering patients and improve their quality of life. Although these treatments are not intended to cure the disease itself they are intended to treat the side effects and symptoms such as pain and stress. The primary objective of cancer supportive care is to enhance the quality of life of the patient. In the recent past, cancer supportive care has become a crucial part of cancer treatment.
Get Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2013
Government organizations and institutions are involved in promoting better supportive care to improve patients’ quality of life. For instance, in 2007, the American Cancer Society collaborated with various institutions including National Palliative Care Research Center (NPCRC) to enhance the cancer supportive care and to promote palliative care. Moreover, the American Cancer Society Cancer Action Network (ACS CAN) is working to improve access to palliative care services for adults and children that are severely suffering from various types of cancer.
Commercially available cancer supportive care drugs include, Granocyte, Neupogen, Zarzio, Pegfilgrastim, Longquex, Aranesp, Epogen, and other categories such as antiemetic’s, NSAID’s, and opioids.
Global Cancer Supportive Care Drugs Market Drivers
Increasing prevalence of various types of cancer is expected to drive growth of the global cancer supportive care drugs market. Cancer is one of the most prevalent fatal chronic disease in the world with a high mortality rate, owing to its invasive nature and extended duration of disease. According to the National Cancer Institute, in 2018, around 1,735,350 new cancer cases were expected to be diagnosed in the U.S. Lung cancer, breast cancer, prostate cancer, melanoma, and bladder cancer are some of the common cancers.
Cancer treatment includes chemotherapy, targeted therapy, radiation therapy, and hormone replacement therapy. These therapies come with significant advantages and side effects. Cancer supportive care drugs used to aid the treatment and reduce the side effects associated with the cancer drugs and treatment. Growing demand for various cancer therapies, owing to high prevalence of the disease is expected to drive the global cancer supportive care drugs market growth during the forecast period. For instance, According to American Cancer Society, in 2017, around 222,500 new cases of lung cancer were reported and around 155,870 deaths recorded due to lung cancer in the U.S.
Moreover, medications such as erythropoietin stimulating agents have been listed into the World Health Organizations’ (WHO) essential medicine list and are indicated for the treatment of anemia due to chemotherapy and other treatments. Efficacy of biopharmaceutical drugs such as erythropoietin stimulating agents and g-colony stimulating factors in the treatment of cancer-induced side effects (anemia) are expected to drive the global cancer supportive care drugs market growth during the forecast period.
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2013
However, increasing launch of biosimilar in categories such as erythropoietin stimulating agents and g-colony stimulating factors is expected to restrain the global cancer supportive care drugs market growth over the forecast period, as biosimilars are relatively cheaper than these aforementioned drugs. For instance, in 2017, Hospira’s Epogen biosimilar received the U.S. Food & Drug Administration (FDA) approval. Moreover, in 2015, Sandoz launched Zarxio (Filgrastim-sndz), a biosimilar of Filgrastim.
Global Cancer Supportive Care Drugs Market Regional Insights
North America and Europe are expected to register significant growth in the global cancer supportive care drugs market over the forecast period. This growth is attributed to increasing new product launches of cancer supportive care drugs and increasing demand for such drugs, owing to high prevalence of the disease. For instance, according to the American Cancer Society, in 2017, around 225,000 cases of lung cancer were reported in the U.S. Furthermore, presence of leading pharmaceutical companies such as Amgen, Inc. in North America that are involved in research and development activities of new cancer supportive care drugs is a key factor driving growth of the market in the region over the forecast period.
However, increasing competition to international manufactures from generic manufacturers in India and China is expected to hinder growth of the global cancer supportive care drugs market during the forecast period.
Global Cancer Supportive Care Drugs Market Key Player
Key players operating in the global cancer supportive care drugs market include Johnson & Johnson, Novartis AG, F.Hoffmann La-Roche Ltd., Amgen, Inc., Baxter International, Inc., Teva Pharmaceutical Industries Ltd., Acacia Pharma Ltd., Merck & Co., Inc., Helsinn Healthcare SA, and Heron Therapeutics.
Global Cancer Supportive Care Drugs Market Taxonomy
The global cancer supportive care drugs market is segmented on the basis of drug type, cancer type, distribution channel, and region.
By Drug Type –
- G-Colony Stimulating Factors
- Erythropoietin Stimulating Agents
By Cancer Type –
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Bladder Cancer
- Ovarian Cancer
By Distribution Channel –
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region –
- North America
- Asia Pacific
- Latin America
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire